GSTM1 and acute myeloid leukemia: For patients with wild-type NPM1 AML, there was a trend for lower median WBC for true negatives (3.54 GPt/l [IQR: 1.52–19.82] vs. false positives 11.3 GPt/l [IQR:3.95–36.849], p = 0.095), but age, sex, ELN2017 risk category, AML type (de novo, secondary or therapy-associated), absence or presence of a complex karyotype, bone marrow or peripheral blast count, Hb and platelet count showed no differences.